Intravitreally administered injections of the selective vascular endothelial growth factor (VEGF)-165 inhibitor pegaptanib significantly reduces foveal thickness and improves visual acuity in patients with diabetes and macular edema.
Sign in with your MPR account
Keep me signed in Forgot your password?
REGISTER FOR FREE WITH A MPR ACCOUNT
Enter your MPR registration email address to receive a new password.